Oulu, Finland

Kari I Kivirikko

This inventor holds 8 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignees: Fibrogen, Inc., Hoechst Aktiengesellschaft, Thomas Jefferson University. Active years: 1988-2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kari I Kivirikko. Retrieved from https://idiyas.com/inventor/kari-i-kivirikko

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

 

 

Average Co-Inventor Count = 5.6

ph-index = 6

Forward Citations = 181(Granted Patents)


Location History:

  • Laamsantie, FI (1995)
  • Oulu, FI (1988 - 2008)

Company Filing History:


Years Active: 1988-2008

Loading Chart...
Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Journey of Kari I Kivirikko

Introduction: Kari I Kivirikko, a pioneering inventor hailing from Oulu, Finland, has made significant contributions to the field of science and technology.

Latest Patents: Kari I Kivirikko's latest patents focus on cutting-edge advancements in biotechnology and medical devices, showcasing her commitment to innovation.

Career Highlights: Throughout her illustrious career, Kari I Kivirikko has been recognized for her groundbreaking work in biochemistry, leading to the development of revolutionary products that have transformed the industry.

Collaborations: Kari I Kivirikko has collaborated with top research institutions and universities worldwide, fostering a culture of innovation and knowledge-sharing in the scientific community.

Conclusion: Kari I Kivirikko's dedication to pushing the boundaries of invention and her unwavering commitment to excellence continue to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…